Stakeholders in PREFER

The PREFER project starts and ends with stakeholders. Their input is crucial for this project to succeed. The project includes partners representing patient organisations and clinical research, HTA bodies and industry. We also have stakeholder advisory groups for patients, regulators, HTA-bodies and payers. With them on board, we trust our results will be relevant and useful.

Patients, HTA bodies and regulators will all be closely involved in the project. The work starts with focus groups and interviews with patient organisations, physicians, regulatory authorities, health technology assessment bodies, industry experts and academics. This will give us knowledge of what their needs are, and how they want to use patient preferences. It will also give us knowledge about what stakeholders are concerned about, and what they expect from our assessment of patient preferences.

In the next step, we move on to test preference-elicitation methods in clinical case studies. Here, patient and clinical research partners are directly involved in the work. Advisory groups will play important roles in designing the work and helping us get input from a wider community of stakeholders.

With this input, we trust that the recommendations we produce at the end of the project will be relevant and useful.





  • Disclaimer: This website and its contents reflects the PREFER project's view and not the view of IMI, the European Union or EFPIA.


The Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115966. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).